9 out of 10
adult patients were at high risk at baseline
of adult patients had normal uric acid levels (≤7.5 mg/dL) at baseline
Adult patients meeting at least 1 of the following criteria were enrolled in the pivotal trial1:
Aggressive lymphoma/leukemia (defined by REAL)
Elevated plasma uric acid levels (>7.5 mg/dL) at baseline
High-grade MDS with >10% bone marrow blast involvement
CML in blast crisis
INTERMEDIATE (POTENTIAL) RISK1
Aggressive lymphoma/leukemia, not limited to the REAL definition, with LDH ≥2x the upper limit of normal
Any stage III to IV lymphoma or leukemia
Stage I or II disease with bulky lymph node/tumor (>5 cm) involvement
AML=acute myeloid leukemia; CLL=chronic lymphocytic leukemia; CML=chronic myeloid leukemia; DLBCL=diffuse large B-cell lymphoma; MDS=myelodysplastic syndrome; REAL=Revised European American Classification of Lymphoid Neoplasms.
WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS
ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).
Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.
USE IN SPECIFIC POPULATIONS